Pet IL-23 Therapeutic Antibody Development

Creative Biolabs offers fully integrated discovery and development solutions tailored to therapeutic antibody programs in veterinary medicine. Our specialized platforms, services, and scientific expertise enable the advancement of innovative biologics designed for companion animals. By focusing on critical immunological targets such as IL-23, we support the development of novel treatments that address chronic inflammatory and immune-related disorders in dogs and cats. Our mission is to accelerate breakthroughs from target validation to preclinical evaluation, helping veterinary researchers and pharmaceutical innovators bring transformative therapies to market. For project-specific discussions or feasibility inquiries, our scientific team is available to provide detailed guidance.

Platforms in Therapeutic Antibody Discovery

We provide multiple robust discovery platforms optimized for canine and feline systems. Each platform can be customized to align with client goals, whether focused on early-stage discovery or progression into advanced engineering and optimization stages.

• Phage Display: Our proprietary canine and feline antibody libraries enable the efficient identification of high-affinity binders with target specificity. This platform ensures broad coverage, reproducibility, and seamless downstream adaptability for engineering or optimization.
• Single-B Cell Sorting: Leveraging flow cytometry and molecular cloning, this platform isolates naturally occurring antibody sequences from B cells, offering a diverse repertoire of candidates with physiological relevance. It provides a powerful route to generate species-specific antibodies optimized for therapeutic applications.
• Hybridoma Technology: By generating monoclonal antibodies through hybridoma approaches, we supply stable, high-quality antibody leads suitable for engineering, affinity maturation, and functional testing. This classic yet reliable platform remains a cornerstone for antibody discovery in veterinary applications.

Comprehensive Antibody Development Services

Our services encompass the complete therapeutic antibody development cycle. Our end-to-end solutions support both discovery-stage projects and late-stage development pipelines.

Antibody Characterization

In-depth assessment of binding affinity, specificity, isotype, and stability using state-of-the-art bioanalytical methods.

Antibody Engineering

Optimization for improved pharmacokinetics, reduced immunogenicity, and enhanced functional activity tailored to veterinary needs.

Preclinical Evaluation

Efficacy, safety, and dosing studies in relevant in vitro models and animal models to generate translational insights for veterinary applications.

Antibody Development

Scalable manufacturing-ready processes ensuring reproducibility, consistency, and compliance with regulatory standards.

Discover How We Can Help - Request a Consultation

Why Focus on IL-23?

IL-23 is a pro-inflammatory cytokine composed of p19 and p40 subunits, playing a pivotal role in the differentiation and survival of Th17 cells. Overactivation of IL-23 pathways has been implicated in autoimmune and chronic inflammatory diseases. In dogs, this includes dermatological conditions such as atopic dermatitis and immune-mediated enteropathies, while in cats, it is associated with gastrointestinal inflammation and other immune-driven disorders. Targeting IL-23 presents an opportunity to develop therapies that precisely modulate pathological immune responses without broadly suppressing protective immunity. Researchers aiming to expand their veterinary immunology pipelines will find IL-23 a compelling therapeutic target for companion animals.

Mechanism of Action

Therapeutic antibodies against IL-23 act by binding to its p19 subunit, thereby preventing the interaction of IL-23 with its receptor complex. This blockade disrupts downstream signaling cascades that drive Th17 differentiation, pro-inflammatory cytokine release, and chronic immune activation. The selective targeting of IL-23 spares other immune pathways, allowing for more controlled modulation of inflammation. In canine and feline contexts, this approach can alleviate symptoms of chronic skin, gastrointestinal, or systemic inflammatory diseases while preserving host defense mechanisms. Partnering with Creative Biolabs ensures precise mechanistic evaluation of antibody candidates during discovery and development phases.

Fig 1. IL‐23p19 mRNA expression levels in duodenal biopsies of healthy cats and cats with inflammatory enteropathy.¹

Our Advantages

• Species-Specific Expertise: Our platforms and services are tailored to canine and feline immunology, ensuring relevance and translational accuracy.
• Integrated Solutions: From early discovery to preclinical evaluation, we provide seamless workflows under one roof, saving time and reducing risk.
• Customizable Approaches: Flexible engagement models designed to match the needs of biotech startups, academic researchers, or pharmaceutical companies.
• Cutting-Edge Technologies: Advanced screening, engineering, and bioanalytical capabilities guarantee high-quality, data-driven outcomes.
• Collaborative Support: Our scientific team works closely with clients, offering continuous updates and scientific consultation throughout the program.

Partner with Creative Biolabs

Therapeutic innovation in veterinary medicine requires precision, speed, and expertise. By collaborating with Creative Biolabs, you gain access to specialized antibody discovery platforms, comprehensive development services, and a team dedicated to advancing your IL-23 research programs. Whether your goal is to evaluate early proof-of-concept or advance into preclinical development, we are committed to supporting your vision. Contact us today to discuss your IL-23 therapeutic antibody development project and explore how we can help accelerate your path from discovery to breakthrough veterinary treatment.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Waly, N E et al. "Measurement of IL-12 (p40, p35), IL-23p19, and IFN-γ mRNA in duodenal biopsies of cats with inflammatory enteropathy." Journal of veterinary internal medicine vol. 28,1 (2014): 42-7. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1111/jvim.12221